The Next Phase of Medicare Drug Price Negotiations Is Here

Rachel Sachs breaks down a final rule from CMS establishing the framework for the Medicare Drug Price Negotiation Program and evaluates how the Trump administration’s broader drug pricing policy efforts are shaping up in 2026.

‘The role of activism’

In the latest episode of the “Ideas Matter” podcast, WashU’s Sandro Galea leads a discussion about activism’s role in bringing about positive change in health outcomes and more.

GLP‑1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect

The risk of NAION with GLP-1 drugs is likely real. All the evidence – the FDA’s two analyses, the real-world studies conducted by independent researchers and the fact that two regulators reached the same view independently – points in the same direction. But in terms of the total number of people who are likely to experience this side effect, the risk is small, writes Ziyad Al-Aly.

Callais and the 2026 Midterms

In short, the mid-decade redistricting exacerbated by Callais backfired in the 2026 midterm elections but that does not take away from Callais’s doctrinal damage or its potential consequences in the mid-to-long term, writes Travis Crum.

From curiosity to impact

Lan Yang, professor at Washington University in St. Louis and co-founder of DeepSight Technology, shares her experience of pursuing meaningful results in different ways.

More Than Just Leading a Meeting

Whether in the laboratory, classroom or community, the ability to bring people together around a shared purpose is a skill that can amplify your impact long after the conversation ends, writes Nicoletta Memos.

An Ode to Overhead Projectors

I still cherish the tactile quality of scribbling and scrawling my way through a lecture—the slow reveal of important concepts, the ease of annotating images, even the pen-stained hands, writes Eric Fournier.
View More Stories